Clinical Trial Update: Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria [Phase 1, Phase 2]

View source ↗

Summary

This document reports the termination of a Phase 1/2 clinical trial evaluating Sevuparin/DF02 as an adjunctive therapy for uncomplicated falciparum malaria.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Falciparum Malaria

Drugs mentioned

• Sevuparin/DF02

Snippet

Sponsor: Modus Therapeutics AB | Conditions: Malaria, Falciparum | Phase 1, Phase 2 | Status: TERMINATED